A Phase II Study of Fluorine-18 (18F)-Labeled PSMA-1007 in Patients With Known or Suspected Metastatic Prostatic Carcinoma
Latest Information Update: 18 Jun 2025
At a glance
- Drugs Fluorine-18 PSMA 1007 (Primary)
- Indications Prostate cancer
- Focus Diagnostic use
Most Recent Events
- 12 Jun 2025 Status changed from recruiting to discontinued. (Accrual to the biochemically recurrent and metastatic cohorts complete; however, accrual to the remaining two cohorts was lagging and deemed no longer feasible.)
- 08 Sep 2023 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 Jun 2023 to 7 Sep 2023.
- 08 Sep 2023 Status changed from not yet recruiting to recruiting.